AKTX · Akari Therapeutics plc ADS
View on chartInsiders & Stakes
| Rachelle Suzanne Jacques Director | ▲ Buy | Grant | 1,018,027,792 Shares held | 4/26/2024 | View profile |
| DICICCO WENDY F Interim CFO | ▲ Buy | Grant | 158,473,915 Shares held | 5/1/2024 | View profile |
| Hoyoung Huh | ▲ Buy | Grant | 4,695,854 Shares held | 3/6/2025 | View profile |
| Raymond Prudo-Chlebosz | ▲ Buy | Grant | 2,484,990 Shares held | 3/6/2025 | View profile |
| Sandip I. Patel CFO & General Counsel | ▲ Buy | Grant | 496,499 Shares held | 3/6/2025 | View profile |
| Samir Rashmikant Patel | ▲ Buy | Option Exercise | 98,241 Shares held | 7/7/2026 | View profile |
| Robert B. Bazemore Director | ▲ Buy | Grant | 44,642 Shares held | 3/6/2025 | View profile |
| James R. Neal Director | ▲ Buy | Grant | 36,271 Shares held | 3/6/2025 | View profile |
| Kameel D. Farag Interim CFO | ▲ Buy | Grant | 23,309 Shares held | 8/17/2026 | View profile |
| Abizer Gaslightwala CEO | ▲ Buy | Grant | 14,107 Shares held | 9/29/2026 | View profile |
| Torsten Hombeck CFO | ▲ Buy | Grant | 200 Shares held | 1/10/2025 | View profile |
Transaction History
| Abizer Gaslightwala | ▲ Buy | Grant | 6,430 | $62K | 9/29/2026 |
| Kameel D. Farag | ▲ Buy | Grant | 1,728 | $13K | 8/17/2026 |
| Kameel D. Farag | ▲ Buy | Grant | 1,130 | $13K | 7/16/2026 |
| Samir Rashmikant Patel | ▲ Buy | Option Exercise | 1,209 | $10K | 7/7/2026 |
| Samir Rashmikant Patel | ▲ Buy | Option Exercise | 15,466 | $6 | 7/7/2026 |
| Samir Rashmikant Patel | ▲ Buy | Option Exercise | 5,799 | $2 | 7/7/2026 |
| Kameel D. Farag | ▲ Buy | Grant | 1,570 | $13K | 6/24/2026 |
| Kameel D. Farag | ▲ Buy | Grant | 1,248 | $13K | 6/24/2026 |
| Kameel D. Farag | ▲ Buy | Grant | 1,395 | $13K | 6/24/2026 |
| Kameel D. Farag | ▲ Buy | Grant | 2,539 | $13K | 6/24/2026 |
| Kameel D. Farag | ▲ Buy | Grant | 3,725 | $13K | 6/24/2026 |
| Kameel D. Farag | ▲ Buy | Grant | 7,353 | $28K | 6/24/2026 |
| Kameel D. Farag | ▲ Buy | Grant | 1,000 | $13K | 6/24/2026 |
| Kameel D. Farag | ▲ Buy | Grant | 26,619 | $20K | 11/1/2025 |
| Kameel D. Farag | ▲ Buy | Grant | 32,000 | $24K | 11/1/2025 |
| Kameel D. Farag | ▲ Buy | Grant | 6,277 | $5K | 10/22/2025 |
| Abizer Gaslightwala | ▲ Buy | Open Market | 3,000 | $3K | 8/25/2025 |
| Abizer Gaslightwala | ▲ Buy | Open Market | 8,000 | $7K | 8/22/2025 |
| Abizer Gaslightwala | ▲ Buy | Open Market | 10,000 | $9K | 8/21/2025 |
| Abizer Gaslightwala | ▲ Buy | Open Market | 5,203 | $6K | 6/24/2025 |
| Abizer Gaslightwala | ▲ Buy | Open Market | 943 | $1K | 6/23/2025 |
| Abizer Gaslightwala | ▲ Buy | Open Market | 10,000 | $12K | 6/20/2025 |
| Abizer Gaslightwala | ▲ Buy | Open Market | 15,000 | $18K | 6/17/2025 |
| Abizer Gaslightwala | ▲ Buy | Grant | 25,000 | $30K | 6/13/2025 |
| Abizer Gaslightwala | ▲ Buy | Grant | 20,000 | $25K | 6/12/2025 |
| Abizer Gaslightwala | ▲ Buy | Grant | 20,000 | $25K | 6/10/2025 |
| Sandip I. Patel | ▲ Buy | Grant | 44,642 | $50K | 3/6/2025 |
| Hoyoung Huh | ▲ Buy | Grant | 892,857 | $1000K | 3/6/2025 |
| Raymond Prudo-Chlebosz | ▲ Buy | Grant | 446,428 | $500K | 3/6/2025 |
| Samir Rashmikant Patel | ▲ Buy | Grant | 406,250 | $455K | 3/6/2025 |
| James R. Neal | ▲ Buy | Grant | 4,464 | $5K | 3/6/2025 |
| Robert B. Bazemore | ▲ Buy | Grant | 44,642 | $50K | 3/6/2025 |
| Abizer Gaslightwala | ▲ Buy | Grant | 133,928 | $150K | 3/6/2025 |
| Abizer Gaslightwala | ▲ Buy | Grant | 11,439 | $14K | 1/10/2025 |
| Torsten Hombeck | ▲ Buy | Grant | 200 | $244 | 1/10/2025 |
| James R. Neal | ▲ Buy | Grant | 8,000,000 | $5K | 1/9/2025 |
| Abizer Gaslightwala | ▲ Buy | Grant | 1,720,000 | $1K | 1/3/2025 |
| Samir Rashmikant Patel | ▲ Buy | Grant | 208,000 | $125 | 1/3/2025 |
| Samir Rashmikant Patel | ▲ Buy | Grant | 400,000 | $200 | 12/27/2024 |
| Abizer Gaslightwala | ▲ Buy | Grant | 40,000,000 | $20K | 12/27/2024 |
| Samir Rashmikant Patel | ▲ Buy | Grant | 3,200,000 | $2K | 12/26/2024 |
| Abizer Gaslightwala | ▲ Buy | Grant | 30,000,000 | $15K | 12/26/2024 |
| Samir Rashmikant Patel | ▲ Buy | Grant | 7,500,000 | $4K | 12/24/2024 |
| James R. Neal | ▲ Buy | Grant | 2,000,000 | $1K | 12/23/2024 |
| Samir Rashmikant Patel | ▲ Buy | Grant | 1,400,000 | $700 | 12/23/2024 |
| Samir Rashmikant Patel | ▲ Buy | Grant | 1,400,000 | $700 | 12/20/2024 |
| Raymond Prudo-Chlebosz | ▲ Buy | Grant | 419,286,000 | $503K | 12/2/2024 |
| Samir Rashmikant Patel | ▲ Buy | Grant | 419,286,000 | $503K | 12/2/2024 |
| Samir Rashmikant Patel | ▲ Buy | Grant | 1,404,622,000 | — | 11/14/2024 |
| Samir Rashmikant Patel | ▲ Buy | Grant | 91,396,000 | $0 | 6/30/2024 |
| Raymond Prudo-Chlebosz | ▲ Buy | Grant | 1,326,258,000 | $1.2M | 5/31/2024 |
| Samir Rashmikant Patel | ▲ Buy | Grant | 1,326,258,000 | $1.2M | 5/31/2024 |
| DICICCO WENDY F | ▲ Buy | Grant | 158,473,915 | $0 | 5/1/2024 |
| Rachelle Suzanne Jacques | ▲ Buy | Grant | 479,569,892 | $0 | 4/26/2024 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Akari Therapeutics Files New Patent Application
Akari Therapeutics has submitted a new patent application to expand its intellectual property portfolio. This move is relevant as it aims to strengthen the company's long-term position in its therapeutic areas. The stock currently trades well below its 52-week high, reflecting the significant volatility seen in the sector.
Akari Therapeutics Files New Patent Application. Akari Therapeutics has submitted a new patent application to expand its intellectual property portfolio. This move is relevant as it aims to strengthen the company's long-term position in its therapeutic areas. The stock currently trades well below its 52-week high, reflecting the significant volatility seen in the sector.